![Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom - eBioMedicine Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom - eBioMedicine](https://www.thelancet.com/cms/asset/ed9fb7c0-6950-4f6d-a114-f54b85a105fe/gr1.jpg)
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom - eBioMedicine
![More than 10 years after introduction of an acellular pertussis vaccine in infancy: a cross-sectional serosurvey of pertussis in the Netherlands - The Lancet Regional Health – Europe More than 10 years after introduction of an acellular pertussis vaccine in infancy: a cross-sectional serosurvey of pertussis in the Netherlands - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/asset/a73ff9b8-dea5-48bd-8b2c-d3ac4908c6dc/gr1.jpg)
More than 10 years after introduction of an acellular pertussis vaccine in infancy: a cross-sectional serosurvey of pertussis in the Netherlands - The Lancet Regional Health – Europe
![Want to mix and match booster shots? Here's why public health officials aren't letting you — yet | Salon.com Want to mix and match booster shots? Here's why public health officials aren't letting you — yet | Salon.com](https://mediaproxy.salon.com/width/1200/https://media.salon.com/2021/10/covid-19-coronavirus-vaccine-shot-bottle-syringe-1018211.jpg)
Want to mix and match booster shots? Here's why public health officials aren't letting you — yet | Salon.com
![Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial - Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -](https://www.thelancet.com/cms/attachment/60780324-d5d9-4b6a-a956-6f87101bc7c8/gr2.jpg)